Pharmacogenomic analysis of alarelin acetate-induced hepatotoxicity: a case report and literature review.

ABSTRACT:

Background

Alarelin acetate, a synthetic gonadotropin-releasing hormone (GnRH) analogue, is widely used to manage endometriosis and hormone-sensitive malignancies. Although its safety profile is generally favorable, we report the first documented case of severe hepatotoxicity associated with alarelin acetate administration.

Case summary

A 37-year-old female participant in a phase I clinical trial developed acute hepatocellular injury following subcutaneous administration of alarelin acetate (150 μg/day). The Roussel Uclaf Causality Assessment Method (RUCAM) yielded a score of 6, indicating a "highly probable" causal relationship between the drug and liver injury. Hepatic enzyme levels normalized within 18 days after drug discontinuation and initiation of hepatoprotective the

SUBMITTER: Yuan F 

PROVIDER: S-EPMC12515876 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature